Clinical trials: Food Safety
Immune System Diseases
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies.
- Trial name
- NCT01510626
- Testing
- Food proteins, Omalizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Healthy
Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men
This study evaluates the effect of Lu AF88434 on the body and what the body does to Lu AF88434 and the effect of food after swallowing single oral doses
- Trial name
- NCT04082325
- Testing
- Lu AF88434, Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434), Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
- Where
- Netherlands
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Malaria
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy…
- Trial name
- NCT07758985
- Testing
- Cohort 1 low dose lotilaner with a high-fat meal, Cohort 2 high dose lotilaner in fasted state, Cohort 3 high dose lotilaner with a high-fat meal
- Where
- Mali
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Healthy Volunteers
Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)
Evaluation of the potential effect that the administration of food or antacid medication may have in the oral absorption of dacomitinib relative to the administration of dacomitinib in absence of food or antacid medication
- Trial name
- NCT01702506
- Testing
- dacomitinib fasted, dacomitinib fed, dacomitinib+antacid
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Ulcerative Colitis, Inflammatory Bowel Diseases
Open Label Study to Assess Safety & Efficacy of QD for Induction of Remission in Pediatric Patients with UC
To date, there are no reports on the use of QD in pediatric patients with UC. There is a great need to increase the repertoire of anti-inflammatory interventions for remission induction, especially in children given the notorious…
- Trial name
- NCT06777706
- Testing
- QD (Qing Dai)
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Shaare Zedek Medical Center
Chronic Idiopathic Constipation
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants
This study aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties and food effect of IN-114199 in healthy participants
- Trial name
- NCT06736912
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Hyperkalemia
Patiromer With or Without Food for the Treatment of Hyperkalemia
The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high…
- Trial name
- TOURMALINE (NCT02694744)
- Testing
- patiromer
- Where
- 29 sites in United States
- Volunteers
- 114 people
- Sponsor
- Relypsa, Inc.
Pharmacokinetics of New Curcumin Formulations, Safety of New Curcumin Formulations
Improved Oral Bioavailability of Curcumin Incorporated Into Micelles
Curcumin, a lipophilic polyphenol derived from the plant curcuma longa possesses numerous health-promoting activities. The oral bioavailability of curcumin is low due to its poor aqueous solubility, limited gastrointestinal…
- Trial name
- NCT01982734
- Testing
- curcumin
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Hohenheim
Allergy;Food, Adherence, Treatment
The Food Allergy Superheroes Training (FAST) Program
Among children with a food allergy, strict avoidance (e.g., elimination of allergenic foods from one's diet) is the only intervention capable of preventing potentially devastating health-related sequelae including anaphylaxis and…
- Conditions
- Allergy;Food, Adherence, Treatment, Child, Only
- Trial name
- NCT04400214
- Testing
- Food Allergy Superheroes Training (FAST) Program, Food Allergy Knowledge Intervention
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Kent State University
To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease, Anemia, Sickle Cell
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
This is an open-label study to understand the safety and tolerability of AXA4010, a novel composition of amino acids in adult and adolescent subjects with sickle cell disease over 12 weeks.
- Conditions
- To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease, Anemia, Sickle Cell, Sickle Cell Anemia, Sickle Cell Disorders
- Trial name
- NCT04134299
- Testing
- AXA4010
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Axcella Health, Inc
Chronic Hepatitis b
Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects
The study is a randomized, Double-Blind, Placebo-Controlled study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and food effect of HRS9950.
- Trial name
- NCT04464733
- Testing
- HRS9950
- Where
- China
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
This is a Phase I, randomized, subject-blinded, placebo controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD),and food effect (FE) of HSK39297 following (1) a single ascending dose (part…
- Trial name
- NCT06350279
- Testing
- HSK39297
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Alopecia Areata
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
This first in human phase 1 study to Study will evaluate safety, tolerability, and pharmacokinetics of Single Ascending dose (SAD), Food effect (FE) and Multiple ascending dose (MAD) of OR-101 Administered Orally in healthy…
- Trial name
- NCT06045624
- Testing
- OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose)
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ornovi, Inc.
Filariasis
Relative Bioavailability Study of Emodepside IR-tablets and Solution
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov…
- Trial name
- NCT03383523
- Testing
- Emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Healthy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
The purpose of this study is to evaluate the safety and tolerability of ascending doses of the MEK-inhibitor zapnometinib (ATR-002) given as single doses (SAD Part) and as multiple doses for 7 days (MAD Part) in healthy subjects.
- Trial name
- NCT05555823
- Testing
- ATR-002, Repaglinide, Celecoxib
- Where
- Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Atriva Therapeutics GmbH
Food Intolerance, Celiac Disease
"Gluten Friendly" Treatment in Celiac Disease
A PROSPECTIVE, double blind, placebo-controlled trial
- Trial name
- GLUFR (NCT03137862)
- Testing
- Gluten free bread, Gluten friendly bread 3g/day, Gluten friendly bread 6g/day
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Healthy Subjects
A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06427878 in healthy adult…
- Trial name
- NCT02391623
- Testing
- PF-06427878
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overactive Bladder
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
This is a two-part study. Part 1 is designed to find the best modified release formulation of GW423753; Part 2 is designed to use the selected formulation(s) from Part 1 to find out if food affects the way the medication is…
- Trial name
- NCT00427596
- Testing
- Solabegron
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
HS-10542 Study in Healthy Participants
This is a randomized, double-blind, placebo-controlled, dose escalation phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and the food effect on the pharmacokinetics of HS-10542 in healthy…
- Trial name
- NCT07040046
- Testing
- HS-10542
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Celiac Disease, Celiac
A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)
A randomized, double-blind, placebo-controlled clinical study in human leukocyte antigen (HLA)-DQ 2.5+ adults with celiac disease (CeD).
- Conditions
- Celiac Disease, Celiac, Intestinal Disease, Malabsorption Syndromes
- Trial name
- NCT03644069
- Testing
- Nexvax2
- Where
- 41 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- ImmusanT, Inc.